Post-earnings recap
Reported
Mon, Nov 10, 2025
EPS actual
$-0.27
EPS est.
$-0.30
EPS surprise
+10.00%
1-day move
+3.52%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Terns Pharmaceutical's earnings report showed a smaller-than-expected loss per share, which led to a positive stock reaction, rising 3.52%. The company did not provide revenue figures or future guidance, leaving investors with limited insights into upcoming performance. The focus on operational improvements suggests management is working to stabilize the business amid uncertainties.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | +10.00% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS surprise, highlighting ongoing efforts to improve operations. They emphasized their commitment to pipeline development.
We are pleased with our EPS performance despite the lack of revenue guidance.
Our focus remains on advancing our pipeline and operational efficiency.